<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0702221687
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2002
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        XOLA OPTHALMIC SOLUTION
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DORZOLAMIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        %
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Ophthalmic use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Eye drops, solution
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Dropper Container
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        37.00
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jamjoom Pharmaceuticals Factory Company" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory Company
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 394]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            JAMJOOM PHARMACEUTICALS CO. LTD.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory  Company
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        S01EC03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>XolaTM eye drops are a sterile eye drop solution.<br />XolaTM eye drops contains dorzolamide,<br />a sulphonamide-related compound, as the active<br />ingredient.<br />XolaTM is an ophthalmic carbonic anhydrase<br />inhibitor which reduces high pressure in the eye.<br />It is indicated in the treatment of elevated<br />intra-ocular pressure in conditions such as ocular<br />hypertension and glaucoma (open-angle<br />glaucoma, pseudo-exfoliative glaucoma). XolaTM<br />eye drops can be used alone or in addition to<br />other medicines which lower the pressure in the<br />eye (so-called beta-blockers).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not use XolaTM eye drops if you<br />&bull; are allergic (hypersensitive) to XolaTM or any of<br />the other ingredients in this solution.<br />&bull; have severe kidney problems.<br />Take special care with XolaTM eye drops<br />Before treatment with XolaTM eye drops, tell your<br />doctor if you<br />&bull; have or have had liver problems in the past.<br />&bull; have been told you have a corneal defect.<br />&bull; have had any allergies to any medicines.<br />&bull; have had, or are about to have eye surgery.<br />&bull; have suffered an eye injury or have an eye<br />infection.<br />&bull; have a prior history of kidney stones.<br />&bull; are taking orally another carbonic anhydrase<br />inhibitor.<br />&bull; wear contact lenses (see the section &lsquo;Important<br />information about some of the ingredients of<br />XolaTM eye drops&rsquo;).<br />You should contact your doctor immediately if<br />you develop any eye irritation or any new eye<br />problems such as redness of the eye or swelling<br />of the surface layer of the eye or eyelids.<br />Stop using XolaTM eye drops and contact your<br />doctor immediately if you suspect that XolaTM eye<br />drops are causing an allergic reaction (for<br />example, skin rash, severe skin reactions with<br />blistering of the skin which may affect the mouth,<br />eyes and genitals, itching, inflammation of the<br />eye).<br />Use in children<br />XolaTM eye drops have been studied in infants and<br />children less than 6 years of age who have raised<br />pressure in the eye(s) or have been diagnosed<br />with glaucoma.<br />For more information, talk to your doctor.<br />Using other medicines<br />Please tell your doctor or pharmacist if you are<br />taking or have recently taken any other<br />medicines, including medicines obtained without<br />a prescription.<br />In particular you should tell your doctor if you are<br />taking another carbonic anhydrase inhibitor such<br />as acetazolamide. You may be taking this type of<br />medicine by mouth, as eye drops, or by some<br />other method.<br />Pregnancy and breast-feeding<br />Ask your doctor or pharmacist for advice before<br />taking any medicine. Tell your doctor if you are<br />pregnant or planning to become pregnant. XolaTM<br />eye drops should not be used during pregnancy<br />unless your doctor still recommends it. XolaTM eye<br />drops should not be used while breast-feeding.<br />Driving and using machines<br />XolaTM eye drops may cause dizziness and visual<br />disturbances in some patients. Do not drive or<br />use any tools or machines until the symptoms<br />have cleared.<br />Important information about some of the<br />ingredients of XolaTM eye drops<br />XolaTM eye drops contain the preservative<br />benzalkonium chloride.<br />&bull; Benzalkonium chloride may cause eye irritation.<br />&bull; Benzalkonium chloride is known to discolour<br />soft contact lenses.<br />&bull; Avoid contact with soft contact lenses.<br />&bull; Remove contact lenses prior to application and<br />wait until 15 minutes before reinsertion.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use XolaTM eye drops exactly as your<br />doctor has told you.<br />You should check with your doctor or pharmacist<br />if you are not sure.<br />The appropriate dosage and duration of<br />treatment will be established by your doctor.<br />When XolaTM eye drops are used alone, the usual<br />dose is one drop in the affected eye(s) three times<br />a day, for example in the morning, in the<br />afternoon and in the evening.<br />If your doctor has recommended you use XolaTM<br />eye drops with a beta-blocker eye drop<br />(medicines which lower the pressure of the eye),<br />then the usual dose is one drop of XolaTM eye<br />drops in the affected eye(s) two times a day, for<br />example in the morning and in the evening.<br />If you use XolaTM eye drops with another eye drop,<br />leave at least 10 minutes between putting in<br />XolaTM eye drops and the other medicine.<br />Alternatively if you are going to use XolaTM eye<br />drops to replace another eye drop medicine, used<br />to lower eye pressure, you should stop using the<br />other medicine after using the proper dosing on<br />one day, and start XolaTM eye drops on the next<br />day.<br />Do not change the dosage of the drug without<br />consulting your doctor.<br />If you must stop treatment, contact your doctor<br />immediately.<br />Instructions for using eye drops:<br />&bull; Unscrew the cap from the bottle, check the<br />dropper is clean.<br />&bull; Pull your lower eyelid gently down, and then<br />carefully instil one drop inside the lower eyelid, in<br />the corner closest to the nose.<br />&bull; Release the lower eyelid, and blink a few times<br />to make sure the eye is covered by the liquid.<br />&bull; If you use drops in both eyes, repeat the steps<br />for your other eye.<br />&bull; Put the bottle cap back on firmly immediately<br />after use.<br />If you use more XolaTM eye drops than you should<br />If you put too many drops in your eye or swallow<br />any of the contents, you should contact your<br />doctor immediately.<br />If you forget to use XolaTM eye drops<br />It is important to use XolaTM eye drops as<br />prescribed by your doctor.</p><p>If you miss a dose, apply it as soon as possible.<br />However, if it is almost time for the next dose, skip<br />the missed dose and go back to your regular<br />dosing schedule.<br />Do not use a double dose to make up for forgotten<br />individual doses.<br />If you stop using XolaTM eye drops<br />XolaTM eye drops should be used every day to work<br />properly. If you must stop treatment, contact your<br />doctor immediately.<br />If you have any further questions on the use of this<br />product, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, XolaTM eye drops can cause side<br />effects, although not everybody gets them.<br />Stop using this medicine and seek immediate<br />medical advice if you develop allergic reactions.<br />Symptoms of allergic reactions include the<br />following:<br />&bull; swelling of the face, lips, tongue, and/or throat<br />which may cause difficulty in breathing or<br />swallowing.<br />&bull; severe skin reactions with blistering of the skin<br />which may affect the mouth, eyes and genitals.<br />&bull; hives.<br />The following side effects may be seen with XolaTM<br />eye drops:<br />Very common (affects more than 1 in 10 people)<br />&bull; burning and stinging of the eyes.<br />Common (affects in between 1 and 10 out of every<br />100 people)<br />&bull; disease of the surface layer of the eye with sore<br />eye and blurred vision (superficial punctuate<br />keratitis), inflammation or swelling of the surface<br />layer of the eye(s) and possible inflammation of<br />the eyelid(s) and/or skin around the eye(s),<br />watering or itching of the eye(s), blurred vision,<br />effects on the surface of the eye.<br />&bull; nausea, bitter taste.<br />&bull; weakness/fatigue.<br />&bull; headache.<br />Uncommon (affects in between 1 and 10 out of<br />every 1000 people)<br />&bull; inflammation of the middle layer of the eye.<br />Rare (affects in between 1 and 10 out of every<br />10,000 people)<br />&bull; swelling of the surface layer of the eye(s),<br />separation of part of the lining of the eye due to a<br />build up of fluid (choroidal detachment) which<br />may be accompanied by visual<br />changes/disturbances (following eye surgery), low<br />pressure in the eye (ocular hypotony), redness of<br />the eye(s), eye pain, crusting of the eyelid(s),<br />temporary shortsightedness (which stops when<br />the medicine is discontinued).<br />&bull; throat irritation, dry mouth.<br />&bull; Hypersensitivity: signs and symptoms of local<br />reactions affecting the eye lids (palpebral<br />reactions) and general allergic reactions including<br />swelling of the face, lips, tongue, and/or throat<br />which may cause difficulty in breathing or<br />swallowing, hives and itching, rash, shortness of<br />breath and more rarely wheezing (bronchospasm).<br />&bull; dizziness, numbness/tingling sensation.<br />&bull; formation of kidney stones in the urinary system.<br />&bull; bleeding from the nose.<br />&bull; severe skin reactions, skin inflammation.<br />If any of the side effects gets serious, or if you<br />notice any side effects not listed in this leaflet,<br />please tell your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; Keep out of the reach and sight of children.<br />&bull; Do not store above 30 &ordm;C.<br />&bull; Do not use Xola&trade; after the expiry date which is<br />stated on the bottle and the carton after &lsquo;Exp&rsquo;.<br />&bull; Xola&trade; eye drops are sterile when first opened, it is<br />important to keep the drops as clean as possible<br />during use.<br />&bull; Discard after 30 days of opening the bottle.<br />&bull; Medicines should not be disposed of via waste<br />water or household waste. Ask your pharmacist<br />how to dispose of medicines no longer required.<br />This will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What XolaTM eye drops contains<br />&bull; The active substance is dorzolamide.<br />Each ml contains:<br />Dorzolamide Hydrochloride 22.25 mg<br />(Equivalent to Dorzolamide 20 mg).<br />&bull; The other ingredients are benzalkonium chloride<br />0.075 mg (as preservative), hydroxyethyl cellulose,<br />mannitol, sodium citrate, sodium hydroxide and /<br />or hydrochloric acid (to adjust pH) and water for<br />injection.<br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                 XolaTM Ophthalmic Solution is a clear, colorless,slightly viscous solution and free from particulatematter.• XolaTM Ophthalmic Solution 5 ml filled in HDPEbottle.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorisation Holder and Manufacturer<br />Jamjoom Pharmaceuticals Co.,<br />Jeddah, Saudi Arabia.<br />Tel: +966-12-6081111, Fax: +966-12-6081222.<br />Website: www.jamjoompharma.com<br />To report any side effect(s):<br />&bull; Saudi Arabia:<br />- The National Pharmacovigilance and<br />Drug Safety Centre (NPC)<br />o Fax: +966-11-205-7662<br />o Call NPC at +966-11-2038222,<br />Exts: 2317-2356-2353-2354-2334-2340.<br />o Toll free phone: 8002490000<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc<br />&bull; Other GCC States:<br />&minus; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                03-1-0-2015
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p style="text-align:right">&trade; قطرة للعين هي محلول معقم للعين. تحتوي زولا &trade; زولا<br />قطرة للعين على المادة الفعالة دورزولاميد وهي مادة متعلقة<br />بالسولفونامايدات.<br />الدُّورزولاميد هو من مثبِّطات إنزيم أنهيدراز الكَربونيك في<br />العين والذي يساعد في خفض ضغط العين المرتفع.<br />يوصف لعلاج الضغط المرتفع داخل العين في حالات مثل<br />فرط ضغط العين والجلوكوما &quot;الزرق&quot; (جلوكوما الزاوية<br />المفتوحة، الجلوكوما التقشرية الكاذبة). يمكن أن تُستخدم<br />بمفردها أو بالإضافة إلى أدوية أخرى تستخدم &trade; قطرة زولا<br />لخفض ضغط العين &quot;ولذلك تسمى حاصرات بيتا&quot;.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:right">لا تستخدم زولا اذا كنت:&nbsp;</p><p style="text-align:right">&bull; تعاني من فرط الحساسية للدُّورزولاميد أو أي من مكونات<br />قطرة للعين الأخرى. &trade; زولا<br />&bull; تعاني من مشاكل حادة في الكلى.</p><p style="text-align:right">إتخذ إحتياطات خاصة عند استخدام زولا قطرة للعين:&nbsp;</p><p style="text-align:right">قبل العلاج ب (زولا<br />&bull; كنت تعاني حالياً أو فيما سبق من مشاكل في الكبد.<br />&bull; تم إخبارك بأنك تعاني من عيوب في القرنية.<br />&bull; كان لديك أي نوع من الحساسية تجاه أية أدوية.<br />&bull; قد أجريت أو على وشك إجراء عملية جراحية في العين.<br />&bull; عانيت فيما سبق من جرح في العين أو لديك عدوى بالعين.<br />&bull; لديك تاريخ مسبق لحصوات الكلى.<br />&bull; تتناول مثبِّطات أخرى لإنزيم أنهيدراز الكَربونيك عن<br />طريق الفم.<br />&bull; ترتدي عدسات لاصقة ( إقرأ الجزء الخاص &quot;بمعلومات<br />قطرة للعين&quot;). &trade; هامة عن بعض من مكونات زولا<br />&bull; يجب عليك الاتصال بطبيبك على الفور إذا أُصِبت بأي تهيج<br />في العين أو أي مشاكل جديدة في العين مثل احمرار العين أو<br />تورم في الطبقة السطحية من العين أو الجفون.<br />قطرة للعين واتصل بطبيبك &trade; &bull; توقف عن استخدام زولا<br />قطرة للعين تتسبب &trade; على الفور إذا كنت تشك في أن زولا<br />في حدوث رد فعل تحسسي (على سبيل المثال، طفح جلدي،<br />تفاعلات جلدية شديدة مع ظهور تقرحات في الجلد والتي قد<br />تؤثر على الفم والعينين والأعضاء التناسلية، والحكة،<br />والتهاب في العين).<br />الاستخدام في الأطفال:<br />قطرة للعين في الرضع والأطفال &trade; تم دراسة استخدام زولا<br />أقل من ٦ سنوات من العمر الذين يعانوا من إرتفاع في ضغط<br />العين أو تم تشخيص حالتهم بانهم يعانون من الجلوكوما<br />&quot;المياه الزرقاء&quot;. لمزيد من المعلومات، تحدث مع طبيبك.<br />إستخدام أدوية أخرى:<br />يرجى إخبار طبيبك أو الصيدلي إذا كنت تتناول أو تناولت<br />مؤخراً أي أدوية أخرى، بما في ذلك الأدوية التي يتم<br />الحصول عليها بدون وصفة طبية. ينبغي أن تخبر طبيبك<br />على وجه الخصوص إذا كنت تتناول أي مثبِّطات أخرى<br />لإنزيم أنهيدراز الكَربونيك مثل الأسيتازولاميد والتي يمكن<br />أن تتناولها عن طريق الفم أو كقطرة للعين أو بأي طريقة<br />أخرى.<br />&bull; الحمل والرضاعة الطبيعية:<br />إستشيري طبيبك أو الصيدلي قبل تناول أي دواء. أخبري<br />طبيبك إذا كنتِ حاملا أو تخططين لأن تصبحي حاملا .لا<br />للعين خلال فترة الحمل ما لم &trade; ينبغي استخدام قطرة زولا<br />قطرة &trade; يوصي الطبيب بغير ذلك. لا ينبغي استخدام زولا<br />للعين أثناء فترة الرضاعة الطبيعية.<br />&bull; القيادة و تشغيل الماكينات:<br />قطرة للعين الدوار واضطرابات &trade; قد يسبب استخدام زولا<br />في الرؤية لدى بعض المرضى. لا تقم بالقيادة أو استخدام أي<br />أدوات أو آلات حتى تزول تلك الأعراض.<br />قطرة للعين: &trade; معلومات هامة عن بعض مكونات زولا<br />قطرة للعين على كلوريد البنزالكونيوم &trade; &bull; تحتوي زولا<br />كمادة حافظة.<br />&bull; يمكن أن يتسبب كلوريد البنزالكونيوم في حدوث تهيج<br />بالعين.<br />&bull; كلوريد البنزالكونيوم معروف بأنه يتسبب في تغيير لون<br />العدسات اللاصقة اللينة.<br />قطرة للعين للعدسات اللاصقة. &trade; &bull; تجنب ملامسة زولا<br />قطرة للعين &trade; &bull; انزع العدسات اللاصقة قبل استخدام زولا<br />وانتظر ۱٥ دقيقة قبل إعادة ارتداء العدسات اللاصقة مرة<br />أخرى.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:right">استخدم دائما زولا قطرة للعين تماما كما وصفها لك&nbsp;الطبيب. إذا كنت غير متأكداً فينبغي عليك الرجوع إلى طبيبك<br />أو الصيدلي. سيتم تحديد الجرعة ومدة العلاج المناسبة من<br />قبل الطبيب.<br />قطرة للعين بمفردها تكون الجرعة &trade; عندما تستخدم زولا<br />المعتادة هي نقطة واحدة في العين المصابة أو كلتا العينين<br />المصابتين ثلاثة مرات في اليوم على سبيل المثال في الصباح<br />وبعد الظهر وفي المساء.<br />قطرة للعين مع قطرة &trade; إذا رشح لك طبيبك استخدام زولا<br />أخرى للعين من حاصرات بيتا (وهي عقاقير تعمل على<br />خفض ضغط العين المرتفع)، حينئذ تكون الجرعة المعتادة<br />قطرة للعين هي نقطة واحدة في العين المصابة &trade; من زولا<br />أو كلتا العينين المصابتين مرتين في اليوم على سبيل المثال<br />في الصباح وفي المساء.<br />قطرة للعين مع أي قطرات أخرى &trade; إذا كنت تستخدم زولا<br />للعين فقم بالإنتظار عشر دقائق على الأقل بين استخدام<br />قطرة للعين والنوع الآخر. &trade; زولا<br />قطرة للعين بدلاً من &trade; وبالعكس إذا كنت سوف تستخدم زولا<br />نوع آخر من قطرات العين يستخدم لخفض ضغط العين، فإنه<br />يجب عليك التوقف عن استخدام الدواء الآخر بعد تناول<br />قطرة &trade; الجرعة المناسبة في يوم، البدء في استخدام زولا<br />للعين في اليوم الذي يليه.<br />لا تقم بتغيير جرعة الدواء دون استشارة الطبيب.<br />إذا كنت مضطراً لوقف العلاج، اتصل بطبيبك على الفور.<br />إرشادات استخدام قطرات العين<br />&bull; قم بلف الغطاء من الزجاجة، وتحقق من أن القطارة نظيفة.<br />&bull; إسحب الجفن السفلي إلى أسفل برفق، ومن ثم ضع بعناية<br />قطرة واحدة داخل الجفن السفلي، في الزاوية الأقرب إلى<br />الأنف.<br />&bull; حرر الجفن السفلي، أغلق وافتح العين عدة مرات للتأكد من<br />تغطية العين عن طريق السائل.<br />في كلتا العينين كرر نفس &trade; &bull; إذا كنت تستخدم زولا<br />الخطوات للعين الأخرى.إذا كانت هي أيضاً تحتاج للعلاج.<br />&bull; قم بإعادة غطاء الزجاجة الى مكانه مباشرة بعد الإستخدام<br />وقم بإحكام الغلق.<br />قطرة للعين بكمية أكثر من المطلوب: &trade; إذا استخدمت زولا<br />في عينيك أو ابتلعت أي &trade; إذا وضعت الكثير من قطرة زولا<br />من محتوياتها، يجب عليك الاتصال بطبيبك على الفور.<br />قطرة للعين: &trade; إذا نسيت استخدام زولا<br />قطرة للعين كما هو &trade; من الضروري أن تستخدم زولا<br />موصوف لك من قبل الطبيب.<br />إذا نسيت إحدى الجرعات فقم بأخذها في أسرع وقت ممكن<br />ولكن إذا كان قد حان موعد الجرعة التالية فقم بتفويت<br />الجرعة التي نسيتها و إرجع إلى جدول جرعاتك المعتاد.<br />لا تقم بوضع جرعة مضاعفة لتعويض ما قد تم نسيانه من<br />جرعات.</p><p style="text-align:right">إذا توقفت عن استخدام زولا قطرة للعين</p><p style="text-align:right">&nbsp;يجب أن تُستخدم زولا كل يوم حتى تعمل بالشكل المطلوب.<br />إذا كان يجب عليك التوقف عن العلاج، اتصل بطبيبك على<br />الفور. إذا كان لديك أي أسئلة أخرى عن استخدام هذا<br />المستحضر، فإسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:right">يمكن أن تتسبب زولا قطرة للعين في حدوث اعراذا جانبية&nbsp;مثلها في ذلك مثل كل الأدوية الأخرى بالرغم من عدم<br />تعرض جميع الأشخاص لها.<br />توقف عن استخدام هذا الدواء، واطلب المشورة الطبية على<br />الفور إذا لاحظت ظهور أعراضاً للحساسية.<br />أعراض الحساسية تشمل ما يلي:<br />&bull; تورم في الوجه والشفتين واللسان، و / أو الحلق مما قد<br />يسبب صعوبة في التنفس أو البلع.<br />&bull; تفاعلات جلدية حادة مع ظهور تقرحات في الجلد والتي قد<br />تؤثر على الفم والعينين والأعضاء التناسلية.<br />&bull; شَرَى &quot;بثور&quot;.<br />الآثار الجانبية التالية يمكن ملاحظة ظهورها عند استخدام<br />قطرة للعين: &trade; زولا<br />۱۰ أشخاص) / شائعة جداً: (تؤثر على أكثر من ۱<br />&bull; الشعور بحرقان ووخز في العين.<br />شائعة (تؤثر على ما بين ۱ لكل ۱۰۰ شخص)<br />&bull; إعتلال في الطبقة السطحية من العين مع تقرح بالعين وعدم<br />وضوح في الرؤية (التهاب القرنية المنقط السطحي)، إلتهاب<br />أو انتفاخ للطبقة السطحية من العين وامكانية حدوث التهاب<br />لجفون العين و/أو الجلد المحيط بالعينين، تدميع أو حكة<br />بالعينين، عدم وضوح في الرؤية، آثار على سطح العين.<br />&bull; غثيان و الشعور بمذاق مر.<br />&bull; ضعف / تعب.<br />&bull; صداع.<br />غير شائعة (تؤثر على ما بين ۱ إلى ۱۰ لكل ۱۰۰۰<br />شخص)<br />&bull; إلتهاب في الطبقة الوسطى من العين.<br />نادرة (تؤثر على ما بين ۱ إلى ۱۰ لكل ۱۰۰۰۰ شخص)<br />&bull; تورم للطبقة السطحية من العين أو كلتا العينين، إنفصال<br />لجزء من بطانة العين بسبب تجمع للسوائل (إنفصال مَشيمِيَّةِ<br />العَين) والذي يمكن أن يكون مصحوباً بتغيرات أو<br />اضطرابات في الابصار (تتبع العمليات الجراحية في العين)،<br />ضغط منخفض داخل العين (نَقْصُ ضَغْطِ العَين)، احمرار<br />العينين، ألم في العين، قشور في العين، قِصَرُ البَصَرِ أو<br />النّظَر المؤقت (والذي يختفي بعد التوقف عن استخدام<br />الدواء).<br />&bull; تهيج في الحلق، جفاف بالفم.<br />&bull; فرط في الحساسية: علامات وأعراض لتفاعلات موضعية<br />تؤثر على جفون العين (تفاعلات جفنية) وتفاعلات تحسسية<br />بشكل عام تشمل انتفاخ بالوجه، الشفتين، اللسان<br />و/أو الحلق والذي يمكن أن يتسبب في صعوبة في التنفس أو<br />البلع، شرى و حكة، طفح جلدي، قصور في التنفس ونادراً<br />أزيز (تقلصات في الشعب الهوائية).<br />&bull; دوار، تنميل /شعور بالوخز.<br />&bull; تكون حصوات بالكلى في الجهاز البولي.<br />&bull; نزيف من الأنف.<br />&bull; تفاعلات جلدية حادة، التهابات بالجلد.<br />&bull; إذا لاحظت تحول أي من الآثار الجانبية الى مرحلة أكثر<br />خطورة أو إذا لاحظت حدوث آثار جانبية أخرى غير مدرجة<br />في هذه النشرة يرجى إخبار طبيبك أو الصيدلي بها.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:right">&bull; يحفظ بعيداً عن متناول و مرأى الأطفال.<br />&bull; يحفظ في درجة حرارة لا تزيد عن ۳۰ درجة مئوية.<br />قطرة للعين بعد انتهاء تاريخ الصلاحية و &trade; &bull; لا تستخدم زولا<br />المدون على الملصقة الموجودة على الزجاجة وعلى العبوة<br />. EXP الكرتونية بعد كلمة<br />تكون معقمة عند فتحها لأول مرة، &trade; &bull; قطرات العين زولا<br />من المهم أن تظل القطرات نظيفة بأكبر قدر ممكن خلال<br />الاستخدام.<br />&bull; يتلف الدواء بعد ۳۰ يوماً من فتح الغطاء.<br />&bull; لا يتم التخلص من الأدوية عن طريق مياه الصرف أو<br />النفايات المنزلية. إسأل الصيدلي عن طريقة التخلص من<br />الأدوية الغير مرغوب فيها فسوف تساعد هذه الإجراءات<br />على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:right">ما هي مكونات زولا<br />&bull; المادة الفعالة هي الدورزولاميد.<br />۲۲,۲٥ ملغ هايدروكلوريد الدورزولاميد (يكافئ ۲۰ ملغ<br />دورزولاميد).<br />&bull; المكونات الأخرى هي: كلوريد البنزالكونيوم ۰,۰۷٥ ملغ<br />(كمادة حافظة)، هيدروكسي إيثيل سليلوز، مانيتول، سترات<br />الصوديوم، هيدروكسيد الصوديوم و/أو حمض الهيدروكلوريك<br />( لضبط درجة الحموضة) وماء للحقن</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:right">قطرة للعين، هي محلول رائق، عديم اللون، لزج &trade; &bull; زولا<br />قليلا وخالي من الجسيمات.<br />قطرة للعين، محلول ٥ مل في قطارة من البولي &trade; &bull; زولا<br />إيثيلين عالي الكثافة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="ltr">شركة مصنع جمجوم للأدوية ،<br />جدة، المملكة العربية السعودية.<br />+۹٦٦-۱۲- الهاتف: ٦۰۸۱۱۱۱<br />+۹٦٦-۱۲- فاكس: ٦۰۸۱۲۲۲<br />www.jamjoompharma.com : الموقع الإلكتروني<br />للإبلاغ عن أي أثار جانبيه:<br />&bull; المملكة العربية السعودية:<br />- المركز الوطني للتيقظ و السلامة الدوائية<br />+۹٦٦-۱۱-۲۰٥- فاكس: ۷٦٦۲ o<br />للإتصال بالإدارة التنفيذية للتيقظ وإدارة الأزمات. o<br />+۹٦٦-۱۱- هاتف: ۲۰۳۸۲۲۲۲<br />۲۳٤۰-۲۳۳٤-۲۳٥٤-۲۳٥۳-۲۳٥٦- تحويلة: ۲۳۱۷<br />الهاتف المجاني: ۸۰۰۲٤۹۰۰۰۰ o<br />npc.drug@sfda.gov.sa : بريد إلكتروني o<br />www.sfda.gov.sa/npc : الموقع الالكتروني o<br />&bull; دول الخليج الأخرى:<br />- الرجاء الاتصال بالمؤسسات و الهيئات الوطنية في كل<br />دولة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            03-2015
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Xola Ophthalmic Solution
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each ml contains 20 mg of Dorzolamide (as Hydrochloride)
For a full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Eye drops, solution.
Clear, colorless, slightly viscous solution and free from particulate matter, filled in 10 mL HDPE
opaque bottles with LDPE nozzle and HDPE cap.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Dorzolamide Ophthalmic Solution is indicated:<br />&bull; As adjunctive therapy to beta-blockers,<br />&bull; As monotherapy in patients unresponsive to beta-blockers or in whom beta-blockers are<br />contraindicated,<br />in the treatment of elevated intra-ocular pressure in:<br />&bull; Ocular hypertension,<br />&bull; Open-angle glaucoma,<br />&bull; Pseudo-exfoliative glaucoma.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>When used as monotherapy, the dose is one drop of Dorzolamide in the conjunctival sac of the<br />affected eye(s), three times daily.<br />When used as adjunctive therapy with an ophthalmic beta-blocker, the dose is one drop of<br />Dorzolamide in the conjunctival sac of the affected eye(s), two times daily.<br />When substituting Dorzolamide for another ophthalmic anti-glaucoma agent, discontinue the other<br />agent after proper dosing on one day, and start Dorzolamide on the next day.</p><p>If more than one topical ophthalmic drug is being used, the drugs should be administered at least ten<br />minutes apart.<br />Patients should be instructed to wash their hands before use and avoid allowing the tip of the<br />container to come into contact with the eye or surrounding structures.<br />Patients should also be instructed that ocular solutions, if handled improperly, can become<br />contaminated by common bacteria known to cause ocular infections. Serious damage to the eye and<br />subsequent loss of vision may result from using contaminated solutions.<br />Usage instructions<br />Please follow these instructions carefully when using Dorzolamide eye drops solution. It<br />is recommended that you wash your hands before putting in your eye drops.<br />1. You must not use the bottle if the tamper-proof seal on the bottle neck is broken before you<br />first use it.<br />2. To open the bottle unscrews the cap by turning it until the tamper-proof seal breaks.<br />3. Tilt your head back and pull your lower eyelid down slightly to form a pocket between your<br />eyelid and your eye (Fig. 1).</p><p><img width="198" height="123" alt="" src="data:image/jpeg;base64,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" /></p><p>4. Invert the container, and press gently as shown (Fig. 2) until a single drop as instructed<br />by your doctor is dispensed into your eye. DO NOT TOUCH YOUR EYE OR EYELID<br />WITH THE TIP OF THE CONTAINER.</p><p><img width="189" height="152" alt="" src="data:image/jpeg;base64,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" /></p><p><img width="179" height="144" alt="" src="data:image/jpeg;base64,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" /></p><p>5. Repeat steps 3 and 4 with the other eye if instructed to do so by your doctor.<br />6. Re-close the bottle by turning the cap firmly immediately after use and return the bottle to the<br />original outer carton.<br />7. The dispenser tip is designed to provide a pre-measured drop; therefore, do not enlarge the hole of<br />the dispenser tip.<br />Paediatric use:<br />Limited clinical data in paediatric patients with administration of Dorzolamide three times a day are<br />available. (For information regarding paediatric dosing see section 5.1).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Dorzolamide is contraindicated in patients who are hypersensitive to the active substance or to any
of the excipients.
Dorzolamide has not been studied in patients with severe renal impairment (CrCl < 30 ml/min) or
with hyperchloraemic acidosis. Because Dorzolamide and its metabolites are excreted
predominantly by the kidney, Dorzolamide is therefore contra-indicated in such patients.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Dorzolamide has not been studied in patients with hepatic impairment and should therefore be used<br />with caution in such patients.<br />The management of patients with acute angle-closure glaucoma requires therapeutic interventions in<br />addition to ocular hypotensive agents. Dorzolamide has not been studied in patients with acute<br />angle-closure glaucoma.<br />Dorzolamide contains a sulphonamido group, which also occurs in sulphonamides and although<br />administered topically, is absorbed systemically. Therefore the same types of adverse reactions that<br />are attributable to sulphonamides may occur with topical administration, including severe reactions<br />such as Stevens-Johnson syndrome and toxic epidermal necrolysis. If signs of serious reactions or<br />hypersensitivity occur, discontinue the use of this preparation.<br />Therapy with oral carbonic anhydrase inhibitors has been associated with urolithiasis as a result of<br />acid-base disturbances, especially in patients with a prior history of renal calculi. Although no acidbase<br />disturbances have been observed with dorzolamide, urolithiasis has been reported infrequently.<br />Because dorzolamide is a topical carbonic anhydrase inhibitor that is absorbed systemically, patients<br />with a prior history of renal calculi may be at increased risk of urolithiasis while using dorzolamide.<br />If allergic reactions (e.g. conjunctivitis and eyelid reactions) are observed, discontinuation of<br />treatment should be considered.<br />There is a potential for an additive effect on the known systemic effects of carbonic anhydrase<br />inhibition in patients receiving an oral carbonic anhydrase inhibitor and dorzolamide. The<br />concomitant administration of dorzolamide and oral carbonic anhydrase inhibitors is not<br />recommended.</p><p>Corneal oedemas and irreversible corneal decompensations have been reported in patients with preexisting<br />chronic corneal defects and/or a history of intra-ocular surgery while using<br />DORZOLAMIDE . Topical Dorzolamide should be used with caution in such patients.<br />Choroidal detachment concomitant with ocular hypotony have been reported after filtration<br />procedures with administration of aqueous suppressant therapies.<br />DORZOLAMIDE contains the preservative benzalkonium chloride, which may cause eye<br />irritation. Contact lenses should be removed prior to application and wait at least 15 minutes before<br />reinsertion. Benzalkonium chloride is known to discolour soft contact lenses.<br />Paediatric patients:<br />Dorzolamide has not been studied in patients less than 36 weeks gestational age and less than 1<br />week of age. Patients with significant renal tubular immaturity should only receive Dorzolamide<br />after careful consideration of the risk benefit balance because of the possible risk of metabolic<br />acidosis.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Specific drug interaction studies have not been performed with Dorzolamide .<br />In clinical studies, Dorzolamide was used concomitantly with the following medications without<br />evidence of adverse interactions: timolol ophthalmic solution, betaxolol ophthalmic solution and<br />systemic medications, including ACE-inhibitors, calcium-channel blockers, diuretics, non-steroidal<br />anti-inflammatory drugs including aspirin, and hormones (e.g. oestrogen, insulin, thyroxine).<br />Association between Dorzolamide and miotics and adrenergic agonists has not been fully evaluated<br />during glaucoma therapy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Use During Pregnancy<br />Dorzolamide should not be used during pregnancy. No adequate clinical data in exposed<br />pregnancies are available. In rabbits, Dorzolamide produced teratogenic effects at maternotoxic<br />doses (See Section 5.3)</p><p>Use During Lactation<br />It is not known whether Dorzolamide is excreted in human milk. In lactating rats, decreases in the<br />body weight gain of offspring were observed. If treatment with Dorzolamide is required, then<br />lactation is not recommended.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed. Possible<br />side effects such as dizziness and visual disturbances may affect the ability to drive and use<br />machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Dorzolamide was evaluated in more than 1400 individuals in controlled and uncontrolled clinical<br />studies. In long-term studies of 1108 patients treated with Dorzolamide as monotherapy or as<br />adjunctive therapy with an ophthalmic beta-blocker, the most frequent cause of discontinuation<br />(approximately 3%) from treatment with Dorzolamide was drug-related ocular adverse reactions,<br />primarily conjunctivitis and lid reactions.<br />The following adverse reactions have been reported either during clinical trials or during postmarketing<br />experience:<br />[Very Common: (&ge; 1/10), Common: (&ge; 1/100 to &lt;1/10), Uncommon: (&ge; 1/1,000 to &lt;1/100), Rare:<br />(&ge; 1/10,000 to &lt;1/1,000)]<br />Nervous system disorders:<br />Common: headache<br />Rare: dizziness, paraesthesia<br />Eye disorders:<br />Very Common: burning and stinging,<br />Common: superficial punctate keratitis, tearing, conjunctivitis, eyelid inflammation, eye itching,<br />eyelid irritation, blurred vision<br />Uncommon: iridocyclitis<br />Rare: irritation including redness, pain, eyelid crusting, transient myopia (which resolved upon<br />discontinuation of therapy), corneal oedema, ocular hypotony, choroidal detachment following<br />filtration surgery</p><p>Respiratory, thoracic, and mediastinal disorders:<br />Rare: epistaxis<br />Gastrointestinal disorders:<br />Common: nausea, bitter taste<br />Rare: throat irritation, dry mouth<br />Skin and subcutaneous tissue disorders:<br />Rare: contact dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis<br />Renal and urinary disorders:<br />Rare: urolithiasis<br />General disorders and administration site conditions:<br />Common: asthenia/fatigue<br />Rare: Hypersensitivity: signs and symptoms of local reactions (palpebral reactions) and systemic<br />allergic reactions including angioedema, urticaria and pruritus, rash, shortness of breath, rarely<br />bronchospasm<br />Laboratory findings: Dorzolamide was not associated with clinically meaningful electrolyte<br />disturbances.<br />Paediatric patients:<br />See 5.1.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Only limited information is available with regard to human overdose by accidental or deliberate<br />ingestion of Dorzolamide hydrochloride.<br />Symptoms<br />The following have been reported with oral ingestion: somnolence; topical application: nausea,<br />dizziness, headache, fatigue, abnormal dreams, and dysphagia.<br />Treatment<br />Treatment should be symptomatic and supportive. Electrolyte imbalance, development of an<br />acidotic state, and possible central nervous system effects may occur. Serum electrolyte levels<br />(particularly potassium) and blood pH levels should be monitored.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapuetic group: Antiglaucoma preparations and miotics, Carbonic Anhydrase<br />Inhibitors, Dorzolamide, ATC code: S01EC03<br />Mechanism of action<br />Carbonic anhydrase (CA) is an enzyme found in many tissues of the body including the eye. In<br />humans, carbonic anhydrase exists as a number of isoenzymes, the most active being carbonic<br />anhydrase II (CA-II) found primarily in red blood cells (RBCs) but also in other tissues. Inhibition<br />of carbonic anhydrase in the ciliary processes of the eye decreases aqueous humor secretion. The<br />result is a reduction in intra-ocular pressure (IOP).<br />DORZOLAMIDE contains Dorzolamide hydrochloride, a potent inhibitor of human carbonic<br />anhydrase II. Following topical ocular administration, Dorzolamide reduces elevated intra-ocular<br />pressure, whether or not associated with glaucoma. Elevated intra-ocular pressure is a major risk<br />factor in the pathogenesis of optic nerve damage and visual-field loss. Dorzolamide does not cause<br />pupillary constriction and reduces intra-ocular pressure without side effects such as night blindness,<br />accommodative spasm. Dorzolamide has minimal or no effect on pulse rate or blood pressure.<br />Topically applied beta-adrenergic blocking agents also reduce IOP by decreasing aqueous humor<br />secretion but by a different mechanism of action. Studies have shown that when Dorzolamide is&nbsp;added to a topical beta-blocker, additional reduction in IOP is observed; this finding is consistent&nbsp;with the reported additive effects of beta-blockers and oral carbonic anhydrase inhibitors.</p><p><br />Pharmacodynamic effects<br />Clinical effects:<br />Adult Patients<br />In patients with glaucoma or ocular hypertension, the efficacy of Dorzolamide given t.i.d. as<br />monotherapy (baseline IOP &ge;23 mmHg) or given b.i.d. as adjunctive therapy while receiving<br />ophthalmic beta-blockers (baseline IOP &ge;22 mmHg) was demonstrated in large-scale clinical studies<br />of up to one-year duration. The IOP-lowering effect of Dorzolamide as monotherapy and as<br />adjunctive therapy was demonstrated throughout the day and this effect was maintained during longterm<br />administration. Efficacy during long-term monotherapy was similar to betaxolol and slightly<br />less than timolol. When used as adjunctive therapy to ophthalmic beta-blockers, Dorzolamide<br />demonstrated additional IOP lowering similar to pilocarpine 2% q.i.d.</p><p>Paediatric Patients<br />A 3-month, double-masked, active-treatment controlled, multicentre study was undertaken in 184<br />(122 for Dorzolamide ) paediatric patients from 1 week of age to &lt;6 years of age with glaucoma or<br />elevated intraocular pressure (baseline IOP &ge; 22 mmHg) to assess the safety of DORZOLAMIDE<br />when administered topically t.i.d. (three times a day). Approximately half the patients in both<br />treatment groups were diagnosed with congenital glaucoma; other common aetiologies were Sturge<br />Weber syndrome, iridocorneal mesenchymal dysgenesis, aphakic patients. The distribution by age<br />and treatments in the monotherapy phase was as follows:</p><p>Age cohort &lt; 2 years :&nbsp;</p><p>1) Dorzolamide 2% -&nbsp;N=56 Age range: 1 to 23 months</p><p>2) Timolol -&nbsp;Timolol GS 0.25% N=27 Age range: 0.25 to 22 months</p><p>Age cohort &ge; 2 - &lt; 6 years:</p><p>1) N=66 Age range: 2 to 6 years</p><p>2)Timolol 0.50% N=35 Age range: 2 to 6 years</p><p>Across both age cohorts approximately 70 patients received treatment for at least 61 days and<br />approximately 50 patients received 81-100 days of treatment.<br />If IOP was inadequately controlled on Dorzolamide or timolol gel-forming solution monotherapy, a<br />change was made to open-label therapy according to the following: 30 patients &lt;2 years were<br />switched to concomitant therapy with timolol gel-forming solution 0.25% daily and Dorzolamide<br />2% t.i.d.; 30 patients &ge; 2 years were switched to 2% Dorzolamide /0.5% timolol fixed combination<br />b.i.d (twice a day).<br />Overall, this study did not reveal additional safety concerns in paediatric patients: approximately<br />26% (20% in Dorzolamide monotherapy) of paediatric patients were observed to experience drug<br />related adverse affects, the majority of which were local, non-serious ocular effects such as ocular<br />burning and stinging, injection and eye pain. A small percentage &lt;4% was observed to have corneal<br />oedema or haze. Local reactions appeared similar in frequency to comparator. In post marketing<br />data, metabolic acidosis in the very young particularly with renal immaturity/impairment has been<br />reported.</p><p>Efficacy results in paediatric patients suggest that the mean IOP decrease observed in the<br />Dorzolamide group was comparable to the mean IOP decrease observed in the Timolol group even<br />if a slight numeric advantage was observed for Timolol.<br />Longer-term efficacy studies (&gt;12 weeks) are not available.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Unlike oral carbonic anhydrase inhibitors, topical administration of Dorzolamide hydrochloride<br />allows for the active substance to exert its effects directly in the eye at substantially lower doses and<br />therefore with less systemic exposure. In clinical trials, this resulted in a reduction in IOP without<br />the acid-base disturbances or alterations in electrolytes characteristic of oral carbonic anhydrase<br />inhibitors.<br />When topically applied, Dorzolamide reaches the systemic circulation. To assess the potential for<br />systemic carbonic anhydrase inhibition following topical administration, active substance and<br />metabolite concentrations in red blood cells (RBCs) and plasma and carbonic anhydrase inhibition<br />in RBCs were measured. Dorzolamide accumulates in RBCs during chronic dosing as a result of<br />selective binding to CA-II while extremely low concentrations of free active substance in plasma are&nbsp;maintained. The parent active substance forms a single N-desethyl metabolite that inhibits CA-II<br />less potently than the parent active substance but also inhibits a less active isoenzyme (CA-I). The<br />metabolite also accumulates in RBCs where it binds primarily to CA-I. Dorzolamide binds<br />moderately to plasma proteins (approximately 33%). Dorzolamide is primarily excreted unchanged<br />in the urine; the metabolite is also excreted in urine. After dosing ends, Dorzolamide washes out of<br />RBCs non linearly, resulting in a rapid decline of active substance concentration initially, followed<br />by a slower elimination phase with a half-life of about four months.<br />When Dorzolamide was given orally to simulate the maximum systemic exposure after long-term<br />topical ocular administration, steady state was reached within 13 weeks. At steady state, there was<br />virtually no free active substance or metabolite in plasma; CA inhibition in RBCs was less than that<br />anticipated to be necessary for a pharmacological effect on renal function or respiration. Similar<br />pharmacokinetic results were observed after chronic, topical administration of Dorzolamide.<br />However, some elderly patients with renal impairment (estimated CrCl 30-60 ml/min) had higher<br />metabolite concentrations in RBCs, but no meaningful differences in carbonic anhydrase inhibition<br />and no clinically significant systemic side effects were directly attributable to this finding.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The main findings in animal studies with Dorzolamide hydrochloride administered orally were<br />related to the pharmacological effects of systemic carbonic anhydrase inhibition. Some of these<br />findings were species-specific and/or were a result of metabolic acidosis. In rabbits given<br />maternotoxic doses of Dorzolamide associated with metabolic acidosis, malformations of the<br />vertebral bodies were observed.<br />In clinical studies, patients did not develop signs of metabolic acidosis or serum electrolyte changes<br />that are indicative of systemic CA inhibition. Therefore, it is not expected that the effects noted in<br />animal studies would be observed in patients receiving therapeutic doses of Dorzolamide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>1. Benzalkonium Chloride<br />2. Sodium Citrate<br />3. Mannitol<br />4. Hydroxyethyl Cellulose<br />5. Sodium Hydroxide 1 N and/or Hydrochloric Acid 1N to adjust pH<br />6. Water for Injection</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not Applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years (Unopening)
After First opining:
Discard after 30 days of opening the bottle.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C<br />Keep out of the reach and sight of children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>5ml of Xola Ophthalmic Solution filled in 10ml of HDPE (High Density Polyethylene) opaque<br />bottles with LDPE nozzle and HDPE cap.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jamjoom Pharmaceuticals Company Limited
Plot No. ME 1:3, Phase V, Industrial City, Jeddah
Postal address:
P.O. Box 6267
Jeddah 21442, Saudi Arabia.
Tel: 00966-12-6081111
Fax: 00966-12-6081222
E-mail: jpharma@jamjoompharma.com
Website: www.jamjoompharma.com
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                May-2015
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>